Corvus Pharmaceuticals announced on March 20, 2025, the presentation of additional data from its Phase 1/1b clinical trial of soquelitinib for patients with T cell lymphoma (TCL) at the 16th Annual T-Cell Lymphoma Forum. The data continues to demonstrate strong indications of anti-tumor activity in a significant number of patients.
From 23 evaluable patients at the 200 mg twice-daily dose, an objective response rate (ORR) of 39% was observed, including a 26% complete response rate (CRR). The median progression-free survival (PFS) was 6.2 months, and the 18-month PFS rate was 30%, which compares favorably to reported median PFS rates of 1.6 months for belinostat and 3.5 months for pralatrexate.
Analysis of patient blood samples showed that soquelitinib reduces T cell exhaustion, potentially improving T cell function and anti-tumor immunity. This data supports the ongoing registrational Phase 3 trial of soquelitinib in relapsed peripheral T cell lymphoma (PTCL), for which the FDA has granted Orphan Drug and Fast Track designations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.